Orchestra BioMed Files 8-K
Ticker: OBIO · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1814114
| Field | Detail |
|---|---|
| Company | Orchestra Biomed Holdings, Inc. (OBIO) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
TL;DR
Orchestra BioMed filed an 8-K on 6/11/24 for Reg FD disclosure and financials.
AI Summary
Orchestra BioMed Holdings, Inc. filed an 8-K on June 11, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Health Sciences Acquisitions Corp 2, is incorporated in Delaware and headquartered in New Hope, Pennsylvania.
Why It Matters
This filing indicates Orchestra BioMed Holdings, Inc. is making a regulatory disclosure and submitting financial exhibits, which could contain important updates for investors.
Risk Assessment
Risk Level: low — This is a routine regulatory filing with no immediate indication of significant financial distress or positive news.
Key Numbers
- 001-39421 — SEC File Number (Identifies the company's filing history with the SEC.)
- 92-2038755 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Orchestra BioMed Holdings, Inc. (company) — Registrant
- Health Sciences Acquisitions Corp 2 (company) — Former company name
- June 11, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- New Hope, Pennsylvania (location) — Principal executive offices
FAQ
What specific information is being disclosed under Regulation FD?
The filing does not detail the specific content of the Regulation FD disclosure, only that it is being made.
What financial statements and exhibits are included in this filing?
The filing indicates that financial statements and exhibits are included, but their specific contents are not detailed in the provided text.
When did Orchestra BioMed Holdings, Inc. change its name from Health Sciences Acquisitions Corp 2?
The date of the name change was June 3, 2020.
What is the principal business address of Orchestra BioMed Holdings, Inc.?
The principal executive offices are located at 150 Union Square Drive, New Hope, Pennsylvania 18938.
What is the SIC code for Orchestra BioMed Holdings, Inc.?
The Standard Industrial Classification (SIC) code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-06-11 08:01:30
Key Financial Figures
- $0.0001 — h registered Common stock, par value $0.0001 per share OBIO The Nasdaq Global Mark
Filing Documents
- tm2416935d1_8k.htm (8-K) — 22KB
- tm2416935d1_ex99-1.htm (EX-99.1) — 83KB
- tm2415645d1_ex99-1img001.jpg (GRAPHIC) — 124KB
- tm2415645d1_ex99-1img002.jpg (GRAPHIC) — 218KB
- tm2415645d1_ex99-1img003.jpg (GRAPHIC) — 114KB
- tm2415645d1_ex99-1img004.jpg (GRAPHIC) — 83KB
- tm2415645d1_ex99-1img005.jpg (GRAPHIC) — 145KB
- tm2415645d1_ex99-1img006.jpg (GRAPHIC) — 95KB
- tm2415645d1_ex99-1img007.jpg (GRAPHIC) — 230KB
- tm2415645d1_ex99-1img008.jpg (GRAPHIC) — 166KB
- tm2415645d1_ex99-1img009.jpg (GRAPHIC) — 126KB
- tm2415645d1_ex99-1img011.jpg (GRAPHIC) — 157KB
- tm2415645d1_ex99-1img012.jpg (GRAPHIC) — 136KB
- tm2415645d1_ex99-1img013.jpg (GRAPHIC) — 125KB
- tm2415645d1_ex99-1img014.jpg (GRAPHIC) — 148KB
- tm2415645d1_ex99-1img015.jpg (GRAPHIC) — 129KB
- tm2415645d1_ex99-1img016.jpg (GRAPHIC) — 102KB
- tm2415645d1_ex99-1img017.jpg (GRAPHIC) — 150KB
- tm2415645d1_ex99-1img018.jpg (GRAPHIC) — 143KB
- tm2415645d1_ex99-1img019.jpg (GRAPHIC) — 103KB
- tm2415645d1_ex99-1img020.jpg (GRAPHIC) — 145KB
- tm2415645d1_ex99-1img021.jpg (GRAPHIC) — 154KB
- tm2415645d1_ex99-1img022.jpg (GRAPHIC) — 114KB
- tm2415645d1_ex99-1img023.jpg (GRAPHIC) — 116KB
- tm2415645d1_ex99-1img024.jpg (GRAPHIC) — 136KB
- tm2415645d1_ex99-1img025.jpg (GRAPHIC) — 126KB
- tm2415645d1_ex99-1img026.jpg (GRAPHIC) — 116KB
- tm2415645d1_ex99-1img027.jpg (GRAPHIC) — 88KB
- tm2415645d1_ex99-1img028.jpg (GRAPHIC) — 108KB
- tm2415645d1_ex99-1img029.jpg (GRAPHIC) — 104KB
- tm2415645d1_ex99-1img030.jpg (GRAPHIC) — 99KB
- tm2415645d1_ex99-1img031.jpg (GRAPHIC) — 146KB
- tm2415645d1_ex99-1img032.jpg (GRAPHIC) — 130KB
- tm2415645d1_ex99-1img033.jpg (GRAPHIC) — 127KB
- tm2415645d1_ex99-1img034.jpg (GRAPHIC) — 87KB
- tm2415645d1_ex99-1img035.jpg (GRAPHIC) — 105KB
- tm2415645d1_ex99-1img036.jpg (GRAPHIC) — 122KB
- tm2415645d1_ex99-1img037.jpg (GRAPHIC) — 123KB
- tm2415645d1_ex99-1img038.jpg (GRAPHIC) — 91KB
- tm2415645d1_ex99-1img039.jpg (GRAPHIC) — 108KB
- tm2415645d1_ex99-1img040.jpg (GRAPHIC) — 76KB
- tm2415645d1_ex99-1img041.jpg (GRAPHIC) — 125KB
- tm2415645d1_ex99-1img042.jpg (GRAPHIC) — 137KB
- tm2415645d1_ex99-1img043.jpg (GRAPHIC) — 146KB
- tm2415645d1_ex99-1img044.jpg (GRAPHIC) — 142KB
- tm2415645d1_ex99-1img045.jpg (GRAPHIC) — 112KB
- tm2415645d1_ex99-1img046.jpg (GRAPHIC) — 119KB
- tm2415645d1_ex99-1img047.jpg (GRAPHIC) — 138KB
- tm2415645d1_ex99-1img048.jpg (GRAPHIC) — 111KB
- tm2415645d1_ex99-1img049.jpg (GRAPHIC) — 108KB
- tm2415645d1_ex99-1img050.jpg (GRAPHIC) — 115KB
- tm2415645d1_ex99-1img051.jpg (GRAPHIC) — 143KB
- tm2415645d1_ex99-1img052.jpg (GRAPHIC) — 108KB
- tm2415645d1_ex99-1img053.jpg (GRAPHIC) — 130KB
- tm2415645d1_ex99-1img054.jpg (GRAPHIC) — 123KB
- tm2415645d1_ex99-1img055.jpg (GRAPHIC) — 128KB
- tm2415645d1_ex99-1img056.jpg (GRAPHIC) — 70KB
- tm2415645d1_ex99-1img10.jpg (GRAPHIC) — 293KB
- 0001104659-24-070204.txt ( ) — 10173KB
- obio-20240611.xsd (EX-101.SCH) — 3KB
- obio-20240611_lab.xml (EX-101.LAB) — 33KB
- obio-20240611_pre.xml (EX-101.PRE) — 22KB
- tm2416935d1_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. A copy of a slide presentation that Orchestra BioMed Holdings, Inc. (the "Company") uses at investor and industry conferences and presentations is attached to this Current Report on Form 8-K ("Current Report") as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure. The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Investor Presentation. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORCHESTRA BIOMED HOLDINGS, INC. By: /s/ Andrew Taylor Name: Andrew Taylor Title: Chief Financial Officer Date: June 11, 2024 3